

Robert M. LORENCE et al
Appl. No. 08/260,536
January 4, 2006

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-331 (canceled)

332. (currently amended) A method of treating cancer in a mammal having a tumor comprising administering intravenously to said mammal more than one dose of a pharmaceutical composition comprising live purified Newcastle Disease Virus in an amount sufficient to cause tumor regression.

333. (currently amended) ~~A method as in~~ The method of claim 332, wherein said tumor is selected from the group consisting of: lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma and glioblastoma.

334. (currently amended) ~~A method as in~~ The method of claim 332, wherein said tumor is a colon adenocarcinoma.

335. (currently amended) ~~A method as in~~ The method of claim 332, wherein said tumor is a melanoma.

Robert M. LORENCE et al
Appl. No. 08/260,536
January 4, 2006

336. (currently amended) ~~A method as in~~ The method of claim 332, wherein said tumor is a neuroblastoma.

337. (currently amended) ~~A method as in~~ The method of claim 332, wherein said live purified Newcastle Disease Virus is strain Mass MK107.

338. (currently amended) ~~A method as in~~ The method of claim 332, wherein said live purified Newcastle Disease Virus is strain 73-T.

339-341. (canceled)

342. (currently amended) ~~A method as in~~ The method of claim 332, wherein the amount of live purified Newcastle Disease Virus administered intravenously is about 4×10^{10} to 4×10^{12} PFU/kg.

343-351. (canceled)

352. (currently amended) ~~A method as in~~ The method of claim 332, wherein the live purified Newcastle Disease Virus is administered intravenously in an amount of about 10^8 PFU.

353-366 (canceled)

Robert M. LORENCE et al
Appl. No. 08/260,536
January 4, 2006

367. (currently amended) ~~A method according to~~ The method of claim 332,
further comprising administering a chemotherapeutic agent.

368. (currently amended) ~~A method as in~~ The method of claim 367, where
wherein the chemotherapeutic agent is selected from the group consisting of thiotepa,
busulfan, cyclophosphamide, methotrexate, cytarabine, bleomycin, cisplatin,
doxorubicin, melphalan, mercaptopurine, vinblastine, 5-fluorouracil, ~~taxol~~ paclitaxel, and
retinoic acid.

369. (currently amended) ~~A method as in~~ The method of claim 368, where
wherein the chemotherapeutic agent is 5-fluorouracil.

370. (currently amended) ~~A method according to~~ The method of claim 332,
further comprising administering an immunosuppressive agent.

371. (currently amended) ~~A method as in~~ The method of claim 370, wherein said
immunosuppressive agent is a corticosteroid.

372. (currently amended) ~~A method according to~~ The method of claim 332,
further comprising administering a cytotoxic or cytostatic agent.

373. (currently amended) ~~A method as in~~ The method of claim 372, wherein said
cytotoxic or cytostatic agent is an antibody.

Robert M. LORENCE et al
Appl. No. 08/260,536
January 4, 2006

374. (currently amended) ~~A method as in~~ The method of claim 372, wherein said cytotoxic or cytostatic agent is a cytokine.

375-385. (canceled)

386. (currently amended) ~~A method according to~~ The method of claims 332, wherein said live purified Newcastle Disease Virus is purified from cell culture.

387. (currently amended) ~~A method as in~~ The method of claim 332, wherein said tumor is cervical carcinoma.

388-391. (canceled)

392. (currently amended) ~~A method according to~~ The method of claim 332, wherein said pharmaceutical composition ~~Newcastle Disease Virus is in the form of a composition which~~ consists essentially of live purified Newcastle Disease Virus.

393. (currently amended) ~~A method according to~~ The method of claim 332, wherein said ~~Newcastle Disease Virus is in the form of a~~ pharmaceutical composition also ~~comprising~~ comprises a pharmaceutically acceptable carrier.

Robert M. LORENCE et al
Appl. No. 08/260,536
January 4, 2006

394. (currently amended) ~~A method according to~~ The method of claim 332,
wherein said tumor is a human tumor.

395. (currently amended) ~~A method according to~~ The method of claim 332,
wherein said tumor is greater than 0.6 cm in diameter.

396. (currently amended) ~~A method according to~~ The method of claim 332,
wherein said tumor is a metastatic tumor.

397. (currently amended) ~~A method according to~~ The method of claim 332,
wherein said amount administered is sufficient to cause complete tumor regression.

398. (canceled)

399. (currently amended) ~~A method according to~~ The method of claim 332,
further comprising administering radiation.

400-402. (canceled) .

403. (currently amended) ~~A method according to~~ The method of claims 332,
wherein said ~~administering step causes~~ method results in tumor regression.